Considerations on Immunization and Immunosuppression of Patients With Autoimmune Blistering Diseases During COVID-19 Pandemic in Brazil: Case Report
- PMID: 35495200
 - PMCID: PMC9040448
 - DOI: 10.3389/fmed.2021.811562
 
Considerations on Immunization and Immunosuppression of Patients With Autoimmune Blistering Diseases During COVID-19 Pandemic in Brazil: Case Report
Abstract
Autoimmune blistering diseases comprise a rare group of potentially life-threatening dermatoses. Management of autoimmune disorders poses a challenge in terms of achieving disease control and preventing adverse events. Treatment often requires an individualized approach considering disease severity, age, comorbidities, and infectious risk especially in the context of the ongoing COVID-19 pandemic. Knowledge regarding SARS-CoV-2 infection is still evolving and no specific antiviral therapy is available yet. We report four patients with active disease that required adjustment of treatment during the pandemic to discuss the use of immunosuppressants and immunobiologics, weighing potential risks and benefits of each therapy modality and vaccination status.
Keywords: COVID-19; SARS-CoV-2; autoimmune blistering diseases; immunosuppressants; pemphigus; rituximab; vaccine.
Copyright © 2022 Miyamoto, Santi, Maruta and Aoki.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
              
              
              
              
                
                
                
              
              
              
              
                
                
                References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
